This is in contrast to previous reports that show that loss of sclerostin increases cranial bone growth and regeneration and sclerostin antibodies are used to increase bone mass in clinical trials of osteoporosis and osteogenesis imperfecta (Kang et al., 2018; Scheiber et al., 2019) suggesting that other mechanisms may be involved in bone formation. This evidence concerns the gene SOST and osteogenesis imperfecta.